Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Elicio Therapeutics Inc (ELTX)

Elicio Therapeutics Inc (ELTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 54,279
  • Shares Outstanding, K 10,791
  • Annual Sales, $ 0 K
  • Annual Income, $ -35,200 K
  • EBIT $ -44 M
  • EBITDA $ -43 M
  • 60-Month Beta 0.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.94
  • Number of Estimates 2
  • High Estimate -0.89
  • Low Estimate -0.99
  • Prior Year -3.77
  • Growth Rate Est. (year over year) +75.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.65 +12.69%
on 12/06/24
5.84 -10.27%
on 12/10/24
+0.31 (+6.29%)
since 11/22/24
3-Month
4.05 +29.38%
on 10/30/24
5.84 -10.27%
on 12/10/24
+0.52 (+11.02%)
since 09/24/24
52-Week
2.96 +77.03%
on 02/07/24
11.45 -54.24%
on 05/16/24
-1.21 (-18.76%)
since 12/22/23

Most Recent Stories

More News
Elicio Therapeutics Presents Encouraging Updated Phase 1 Data for ELI-002 Cancer Vaccine at ESMO Immuno-Oncology Congress 2024

Elicio Therapeutics presented positive Phase 1 results for ELI-002, targeting KRAS mutations in high-risk cancer patients.Quiver AI SummaryElicio Therapeutics presented updated Phase 1 data for its cancer...

ELTX : 5.24 (+4.17%)
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024

ELTX : 5.24 (+4.17%)
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment

ELTX : 5.24 (+4.17%)
Elicio Therapeutics: Q3 Earnings Snapshot

Elicio Therapeutics: Q3 Earnings Snapshot

ELTX : 5.24 (+4.17%)
Elicio Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

ELTX : 5.24 (+4.17%)
Elicio Therapeutics Presents Updated Translational Data from ELI-002 Phase 1 AMPLIFY-7P Study at the Society for Immunotherapy of Cancer (“SITC”) 2024 Annual Meeting

ELTX : 5.24 (+4.17%)
Elicio Therapeutics to Present Clinical Data at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting and Stand Up to Cancer (SU2C) Innovation Summit

ELTX : 5.24 (+4.17%)
Elicio Therapeutics Reports Inducement Grants

ELTX : 5.24 (+4.17%)
Elicio Therapeutics Celebrates 13 Years Developing Innovative Cancer Immunotherapies

Boston, Massachusetts () April 24, 2024 -- Elicio Therapeutics, a clinical biotechnology company, commemorates its 13th anniversary of innovative medical research into cancer vaccines.

ELTX : 5.24 (+4.17%)

Business Summary

Elicio Therapeutics is a privately-held clinical-stage biotechnology company. It involved in developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases. Elicio Therapeutics, formerly known as Angion Biomedica Corp, is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 5.56
2nd Resistance Point 5.40
1st Resistance Point 5.32
Last Price 5.24
1st Support Level 5.09
2nd Support Level 4.93
3rd Support Level 4.85

See More

52-Week High 11.45
Fibonacci 61.8% 8.21
Fibonacci 50% 7.20
Fibonacci 38.2% 6.20
Last Price 5.24
52-Week Low 2.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar